An Intentional Poisoning by Lormetazepam in a Patient Treated with Nordiazepam

Phak-Rop Pos Pok; Emilie Berland; Michel Mauras; Magali Valès; Erika Kuhlmann

doi:10.4236/fmar.2014.24018

Home > Journals > Medicine & Healthcare > FMAR

Forensic Medicine and Anatomy Research > Vol.2 No.4, October 2014

An Intentional Poisoning by Lormetazepam in a Patient Treated with Nordiazepam ()

Phak-Rop Pos Pok, Emilie Berland, Michel Mauras, Magali Valès, Erika Kuhlmann

Laboratoire de Police Scientifique de Marseille, Section Toxicologie, Institut National de Police Scientifique, France.

DOI: 10.4236/fmar.2014.24018 PDF HTML XML 3,919 Downloads 4,469 Views

Abstract

A case of suspected poisoning by benzodiazepines is presented in this paper. Toxicological analyses were applied on the blood collected 48 hours after the facts. GC-MS and HPLC-DAD have detected only nordiazepam which was prescribed in the treatment. Therefore, LC-MS/MS has detected lormetazepam and lorazepam (major metabolite of lormetazepam) in addition of nordiazepam. The concentrations of lormetazepam, lorazepam and nordiazepam measured in blood were 6.8, 6.3, and 16.2 ng/mL, respectively. The initial concentration of each drug at the relevant time, has been calculated from these residual concentrations, using an extrapolation approach. According to estimates, only lormetazepam (189 ng/mL) and lorazepam (68 ng/mL), were active at the target moment. A poisoning by lormetazepam was then considered. The more technology we have, the greater chance we have to get an outcome that is favorable to justice.

Keywords

Benzodiazepines, Discrimination between Poison and Medication, LC-MS/MS

Share and Cite:

Pok, P. , Berland, E. , Mauras, M. , Valès, M. and Kuhlmann, E. (2014) An Intentional Poisoning by Lormetazepam in a Patient Treated with Nordiazepam. Forensic Medicine and Anatomy Research, 2, 107-112. doi: 10.4236/fmar.2014.24018.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Quality and Statistics (2013) The DAWN Report. Update on Drug-Related Emergency Department Visits Attributed to Intentional Poisoning. Rockville.
[2]	Lemmer, P., Schneider, S., Mühe, A. and Wennig, R. (2007) Quantification of Lorazepam and Lormetazepam in Human Breast Milk Using GC-MS in the Negative Chemical Ionization Mode. Journal of Analytical Toxicology, 31, 224- 226. http://dx.doi.org/10.1093/jat/31.4.224
[3]	Cabarcos, P., Tabernero, M.J., Alvarez, I., Lopez, P., Fernandez, P. and Bermejo, A.M. (2010) Analysis of Six Benzodiazepines in Vitreous Humor by High Performance Liquid Chromatography-Photodiode-Array Detection. Journal of Analytical Toxicology, 34, 539-542. http://dx.doi.org/10.1093/jat/34.9.539
[4]	Smink, B.E., Mathijssen, M.P.M., Lusthof, K.J., De Gier, J.J., Egberts, A.C.G. and Uges, D.R.A. (2006) Comparison of Urine and Oral Fluid as Matrices for Screening of Thirty-Three Benzodiazepines and Benzodiazepine-Like Substances Using Immunoassay and LC-MS(-MS). Journal of Analytical Toxicology, 30, 478-485. http://dx.doi.org/10.1093/jat/30.7.478
[5]	Schreiber, A., Houssain, E.A. and Gibbons, J. (2009) A Fast and Sensitive LC/MS/MS Method for the Quantitation and Confirmation of 30 Benzodiazepines and Nonbenzodiazepines Hypnotics in Forensic Urine Samples. Applied Biosystems. Application Note. Cliquid Drug Screen & Quant Software for Routine Forensic Toxicology, 1-6.
[6]	McHale, K.J., Ho, J. and Springfield, A. (2007) A Quantitative Screen for Multiple Classes of Illicit Drugs and Their Primary Metabolites in Human Biological Fluids by LC-MS/MS. Thermo Fisher Scientific, Application Note 390.
[7]	Pok, P.-R.P., Mauras, M., De Saint Léger, M.-N., Kuhlmann, E., Charpenel-Durat, C., et al. (2010) Blood Concentration of Clobazam and Norclobazam in a Lethal Case Involving Clobazam, Meprobamate and Clorazepate. Legal Medicine, 12, 300-304. http://dx.doi.org/10.1016/j.legalmed.2010.08.002
[8]	Pok, P.-R.P. (2013) Some Worlds about Postmortem Blood Atropine Concentrations. Forensic Medicine and Anatomy Research, 1, 37-39. http://dx.doi.org/10.4236/fmar.2013.13007
[9]	Dipiro, J.T., Spruill, W.J., Wade, W.E., Boulin, R.A. and Pruemer, J.M. (2010) Concept in Clinical Pharmacokinetics. 5th Edition, ASHP, Lesson 2, 19-27.
[10]	(2012) Half-Life. Drugs Forum. http://www.drugs-forum.com/forum/showwiki.php?title=Half-life
[11]	Vidal^® (2012) Les monographies des spécialités pharmaceutiques du Dictionnaire Vidal^®. 88th Edition, Vidal, France, Nordaz^®, 1577-1578.
[12]	Schulz, M., Iwersen-Bergmann, S., Anderson, H. and Schmoldt, A. (2012) Therapeutic and Toxic Blood Concentrations of Nearly 1000 Drugs and Other Xenobiotics. Critical Care, 16, R136. http://ccforum.com/content/16/4/r136 http://dx.doi.org/10.1186/cc11441
[13]	Vidal^®(2012) Les monographies des spécialités pharmaceutiques du Dictionnaire Vidal^®. 88th Edition, Vidal, France, Seresta^®, 2044-2045.
[14]	Zentiva, Lormetazepam 1 mg Tablets. http://www.medicines.org.uk/emc/medicine/28193/SPC
[15]	Vidal^® (2012) Les monographies des spécialités pharmaceutiques du Dictionnaire Vidal^®. 88th Edition, Vidal, France, Noctamide^®, 1572-1573.
[16]	Moffat, A.C., Osselton, M.D. and Widdop, B. (2004) Clarke’s Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material. 3rd Edition, Pharmaceutical Press, Lormetazepam, London, 1189-1190.
[17]	Moffat, A.C., Osselton, M.D. and Widdop, B. (2004) Clarke’s Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material. 3rd Edition, Pharmaceutical Press, Lorazepam, London, 1187-1188.